INTRODUCTION {#s1}
============

Sepsis consumes considerable health care resources and has a high mortality rate, especially in elderly patients and in infants born pre-term or with low birth weights \[[@R1], [@R2]\]. Lack of early detection is implicated in the high incidences of severe sepsis and septic shock \[[@R3], [@R4]\]. Thus, sepsis-related biomarkers and risk factors must be identified to improve early detection rates. Recent studies have addressed associations between various gene SNPs (single nucleotide polymorphisms) and sepsis risk. Sepsis risk was associated with *TLR4* (toll like receptor 4) SNPs, rs4986790 and rs4986791 \[[@R5]\], but not the *SERPINE1* \[Serpin Peptidase Inhibitor, Clade E (Nexin, Plasminogen Activator Inhibitor Type 1), Member 1\] rs1799768 polymorphism \[[@R6]\].

TNF-α (tumor necrosis factor-α) is important for normal body functions, but is also implicated in some disease mechanisms, including sepsis, diabetes mellitus, and cancer \[[@R7]-[@R11]\]. There are several known SNPs within the *TNF-α* gene, including rs1800629, rs361525, rs1800630, and others \[[@R12]\]. Associations between *TNF-α* SNPs and sepsis risk are still uncertain. *TNF-α* rs1800629 was reported as a sepsis risk factor in severely injured North Indian patients \[[@R13]\], critically ill Japanese patients \[[@R14]\], the Chinese Han population \[[@R15]\], and Turkish children \[[@R16]\]. However, *TNF-α* rs1800629 was also negatively correlated with sepsis susceptibility in preterm infants in Germany \[[@R17]\] and low-birth-weight infants in Hungary \[[@R18]\]. We did not obtain data from genome wide association studies (GWAS) of sepsis-associated SNPs. Thus, our meta-analysis is a relatively objective evaluation of *TNF-α* SNPs in sepsis risk. Our analysis focused on the genetic relationship between sepsis risk and the rs1800629 and rs361525 polymorphisms within the *TNF-α* promoter region, in that sufficient data was only obtained for the meta-analysis of rs1800629, rs361525 polymorphisms, after our data extraction.

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

We identified a total of 834 records by searching six online databases, including PubMed, WOS (Web of Science), EMBASE (Excerpta Medica Database), CNKI (China National Knowledge Infrastructure), WANFANG, and Scopus, during April 2017 (Figure [1](#F1){ref-type="fig"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We included 23 articles that fit our inclusion/exclusion criteria in our meta-analysis \[[@R13]-[@R35]\]. Case/control group characteristics and genotype frequencies are shown in Table [1](#T1){ref-type="table"} and [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. The 23 articles included 15 high quality studies (NOS score \>6 \[[@R14]-[@R19], [@R22], [@R24], [@R25], [@R27], [@R29], [@R30], [@R33]-[@R35]\]) and eight medium quality studies (NOS=5 \[[@R21], [@R23], [@R28]\]; NOS=6 \[[@R13], [@R20], [@R26], [@R31], [@R32]\]).

![Records identification and study inclusion](oncotarget-08-111456-g001){#F1}

###### Characteristics of case-control studies included in this meta-analysis

  First author, year            Ethnicity   SNP         Case   Control   NOS   Genotyping assay
  ----------------------------- ----------- ----------- ------ --------- ----- -----------------------------------------------------------------------------
  Azevedo, 2012 \[[@R19]\]      Caucasian   rs1800629   439    564       7     TaqMan "Assay by Design" system
  Balding, 2003 \[[@R20]\]      Caucasian   rs1800629   183    389       6     PCR-RFLP
  Davis, 2010 \[[@R21]\]        Caucasian   rs1800629   28     53        5     Taqman SNP allele discrimination assay
  Dou, 2007 \[[@R22]\]          Asian       rs1800629   45     60        9     PCR-RFLP
  Duan, 2011 \[[@R23]\]         Asian       rs1800629   131    174       5     PCR-RFLP
  Fu, 2016 \[[@R24]\]           Asian       rs1800629   115    108       7     PCR-RFLP
                                            rs361525    115    108       7     PCR-RFLP
  Gordon, 2004 \[[@R25]\]       Caucasian   rs1800629   212    354       8     PCR-RFLP
                                            rs361525    205    354       8     End-labeled allele-specific probe hybridisation.
  Gupta, 2015 \[[@R13]\]        Asian       rs1800629   25     89        6     PCR-SSP
                                            rs361525    25     89        6     PCR-SSP
  Majetschak, 2002 \[[@R26]\]   Caucasian   rs1800629   14     56        6     Real-time PCR assay with specific fluorescence-labeled hybridization probes
  Mira, 1999 \[[@R27]\]         Caucasian   rs1800629   81     78        7     DGGE analysis
                                            rs361525    59     72        7     DGGE analysis
  Nakada, 2005 \[[@R14]\]       Asian       rs1800629   86     214       7     PCR-RFLP
  O\'Keefe, 2002 \[[@R28]\]     mixed       rs1800629   37     115       5     Pyrosequencing/PCR-RFLP
                                            rs361525    37     114       5     Pyrosequencing
  Peres, 2012 \[[@R29]\]        Caucasian   rs1800629   166    214       8     PCR-RFLP
  Phumeetham, 2012 \[[@R30]\]   Asian       rs1800629   66     101       8     PCR-RFLP
  Schaaf, 2003 \[[@R31]\]       Caucasian   rs1800629   28     50        6     PCR-RFLP
  Schueller, 2006 \[[@R17]\]    Caucasian   rs1800629   67     233       7     PCR-RFLP
  Sipahi, 2006 \[[@R16]\]       Caucasian   rs1800629   53     77        7     PCR-RFLP
  Sole, 2010 \[[@R32]\]         Caucasian   rs1800629   320    1152      6     Rapid cycle real-time PCR
                                            rs361525    320    1172      6     Rapid cycle real-time PCR
  Song, 2012 \[[@R15]\]         Asian       rs1800629   802    600       9     gene sequencing
                                            rs361525    803    598       9     gene sequencing
  Tian, 2015 \[[@R33]\]         Asian       rs1800629   32     50        9     PCR-RFLP
                                            rs361525    32     50        9     PCR-RFLP
  Treszl, 2003 \[[@R18]\]       Caucasian   rs1800629   33     35        7     PCR-RFLP
  Yu,B, 2003 \[[@R34]\]         Asian       rs1800629   40     100       9     PCR-RFLP
  Yu,D, 2007 \[[@R35]\]         Asian       rs1800629   56     60        9     PCR-RFLP

SNP: single nucleotide polymorphisms; NOS: Newcastle-Ottawa Scale; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR-SSP: polymerase chain reaction-sequence specific primer; DGGE: denaturing gradient gel electrophoresis.

*TNF-α* rs1800629 meta-analysis {#s2_2}
-------------------------------

We enrolled 27 case-control studies with 3,404 cases and 5,973 controls \[[@R13]-[@R35]\] in our *TNF-α* rs1800629 meta-analysis (Table [2](#T2){ref-type="table"}). Sepsis risk was increased in the case group in four genetic models: A vs. G (*P* value from association test \<0.001, odds ratio (OR)=1.32, 95% confidence interval (CI) =1.05--1.65); GA vs. GG (*P*\<0.001, OR=1.46, 95% CI=1.19--1.79); GA+AA vs. GG (*P*\<0.001, OR=1.46, 95% CI=1.20--1.78); carrier A vs. carrier G (*P*\<0.001, OR=1.32, 95% CI=1.14--1.54), but not other models (all *P*\>0.05), compared with controls. This suggested that the *TNF-α* rs1800629 G/A genotype was associated with sepsis risk in the overall population.

###### Genetic relationship between *TNF-α* rs1800629 and sepsis risk

  Comparison                    Subgroup        Sample size   Association test                        
  ----------------------------- --------------- ------------- ------------------ ------ ------------- -------------------
  **A vs. G**                   overall         27            3,404/5,973        3.88   **\<0.001**   1.32 (1.05--1.65)
                                PB              17            2,388/3,003        2.68   **0.007**     1.41 (1.10--1.80)
                                HB              9             796/1,818          2.56   **0.010**     1.44 (1.09--1.91)
                                Caucasian       15            1,883/4,191        1.87   0.062         \-
                                Asian           11            1,484/1,667        3.86   **\<0.001**   1.88 (1.36--2.59)
                                Sepsis          3             431/668            0.30   0.766         \-
                                Severe sepsis   9             903/2,934          2.20   **0.027**     1.55 (1.05--2.29)
                                Septic shock    6             450/2,203          0.60   0.549         \-
  **AA vs. GG**                 overall         20            3,047/5,320        1.89   0.058         \-
                                PB              12            2131/2,517         1.51   0.132         \-
                                HB              7             696/1,651          1.21   0.228         \-
                                Caucasian       12            1,783/4,023        0.79   0.430         \-
                                Asian           7             1,227/1,182        2.20   **0.028**     2.25 (1.09--4.63)
                                Sepsis          2             403/650            1.26   0.208         \-
                                Severe sepsis   7             836/2,801          1.13   0.257         \-
                                Septic shock    6             450/2,203          0.44   0.657         \-
  **GA vs. GG**                 overall         27            3,404/5,973        3.67   **\<0.001**   1.46 (1.19--1.79)
                                PB              17            2,388/3,003        2.34   **0.019**     1.42 (1.06--1.89)
                                HB              9             796/1,818          2.84   **0.005**     1.57 (1.15--2.15)
                                Caucasian       15            1,883/4,191        1.64   0.101         \-
                                Asian           11            1,484/1,667        3.74   **\<0.001**   1.96 (1.38--2.78)
                                Sepsis          3             431/668            1.04   0.298         \-
                                Severe sepsis   9             903/2,934          1.89   0.059         \-
                                Septic shock    6             450/2,203          0.57   0.566         \-
  **GA+AA vs. GG**              overall         27            3,404/5,973        3.79   **\<0.001**   1.46 (1.20--1.78)
                                PB              17            2,388/3,003        2.52   **0.012**     1.44 (1.08--1.91)
                                HB              9             796/1,818          2.70   **0.007**     1.55 (1.13--2.12)
                                Caucasian       15            1,883/4,191        1.74   0.082         \-
                                Asian           11            1,484/1,667        3.72   **\<0.001**   1.95 (1.37--2.78)
                                Sepsis          3             431/668            0.76   0.448         \-
                                Severe sepsis   9             903/2,934          2.06   **0.039**     1.55 (1.02--2.34)
                                Septic shock    6             450/2,203          0.57   0.572         \-
  **AA vs. GG+GA**              overall         20            3,047/5,320        1.52   0.128         \-
                                PB              12            2131/2,517         1.43   0.152         \-
                                HB              7             696/1,651          0.81   0.420         \-
                                Caucasian       12            1,783/4,023        0.53   0.594         \-
                                Asian           7             1,227/1,182        1.95   0.051         \-
                                Sepsis          2             403/650            1.35   0.176         \-
                                Severe sepsis   7             836/2,801          1.09   0.278         \-
                                Septic shock    6             450/2,203          0.49   0.621         \-
  **carrier A vs. carrier G**   overall         27            3,404/5,973        3.60   **\<0.001**   1.32 (1.14--1.54)
                                PB              17            2,388/3,003        2.41   **0.016**     1.33 (1.05--1.67)
                                HB              9             796/1,818          2.60   **0.009**     1.35 (1.08--1.70)
                                Caucasian       15            1,883/4,191        1.96   0.050         \-
                                Asian           11            1,484/1,667        3.90   **\<0.001**   1.75 (1.32--2.31)
                                Sepsis          3             431/668            0.33   0.742         \-
                                Severe sepsis   9             903/2,934          2.60   **0.009**     1.30 (1.07--1.58)
                                Septic shock    6             450/2,203          0.11   0.909         \-

PB: population-based control; HB: hospital-based control; OR: odd ratio; CI: confidence interval; -: ORs (95% CIs) not provided for *P*~association~ \>0.05.

Next, we performed meta-analyses stratified as follows: PB (population-based)/HB (hospital-based), Caucasian/Asian, and sepsis/severe sepsis/septic shock. The PB, HB, and Asian patient groups differed from controls in all four models (A vs. G, GA vs. GG, GA+AA vs. GG, carrier A vs. carrier G) (Table [2](#T2){ref-type="table"}, *P*\<0.05, OR\>1). These results showed a positive correlation between the *TNF-α* rs1800629 G/A genotype and sepsis risk in the Asian population. Additionally, in an analysis of eight articles \[[@R13], [@R15], [@R26]-[@R28], [@R31]-[@R33]\] stratified by sepsis severity, "severe sepsis" cases and controls differed in three models: A vs. G (*P*=0.027, OR=1.55), GA+AA vs. GG (*P*=0.039, OR=1.55), and carrier A vs. carrier G (*P*=0.009, OR=1.30) (Table [2](#T2){ref-type="table"}). Figure [2](#F2){ref-type="fig"} and [Supplementary Figures 1--3](#SD1){ref-type="supplementary-material"} show forest plots of ethnicity subgroup analyses.

![*TNF-α* rs1800629 subgroup analysis based on ethnicity using the GA vs. GG genetic model](oncotarget-08-111456-g002){#F2}

*TNF-α* rs361525 meta-analysis {#s2_3}
------------------------------

We enrolled eight case-control studies containing 1,916 cases and 3,372 controls \[[@R13], [@R15], [@R24], [@R25], [@R27], [@R28], [@R32], [@R33]\] in our *TNF-α* rs361525 meta-analysis. Sepsis risk was increased in the AA vs. GG (*P*=0.001, OR=4.24) and AA vs. GG+GA (*P*=0.001, OR=4.24) genetic models, but not A vs. G, GA vs. GG, GA+AA vs. GG, or carrier A vs. carrier G (all *P*\>0.05; Table [3](#T3){ref-type="table"} ). Similarly, for subgroup analyses of sepsis severity, increased risk of severe sepsis or septic shock was only observed in the AA vs. GG and AA vs. GG+GA models (Table [3](#T3){ref-type="table"}, all *P*\<0.05, OR\>1). In contrast, PB subgroup analyses revealed differences in the A vs. G (*P*=0.001, OR=1.52, 95% CI=1.18--1.97), GA vs. GG (*P*=0.006, OR=1.46, 95% CI=1.12--1.91), GA+AA vs. GG (*P*=0.003, OR=1.51, 95% CI=1.15--1.97), and carrier A vs. carrier G (*P*=0.006, OR=1.45, 95% CI=1.11--1.89) models (Table [3](#T3){ref-type="table"}). Asian patient subgroup analyses also showed differences in these four models (all *P*\<0.05, OR\>1). Figure [3](#F3){ref-type="fig"} and [Supplementary Figures 4--6](#SD1){ref-type="supplementary-material"} show forest plots for ethnicity subgroup analyses. These data suggested that the *TNF-α* rs361525 G/A genotype is associated with enhanced risk of sepsis in the Asian population.

###### Genetic relationship between *TNF-α* rs361525 and sepsis risk

  Comparison                    Subgroup        Sample size   Association test                      
  ----------------------------- --------------- ------------- ------------------ ------ ----------- --------------------
  **A vs. G**                   overall         9             1,916/3,372        1.82   0.069       \-
                                PB              5             1,214/1,182        3.20   **0.001**   1.52 (1.18--1.97)
                                HB              3             382/1,018          0.56   0.574       \-
                                Caucasian       4             904/2,413          0.49   0.622       \-
                                Asian           4             975/845            2.68   **0.007**   1.52 (1.12--2.05)
                                Severe sepsis   5             817/2,749          0.17   0.863       \-
                                Septic shock    4             404/2,148          1.33   0.183       \-
  **AA vs. GG**                 overall         6             961/2,552          3.42   **0.001**   4.24 (1.85--9.69)
                                PB              3             296/476            1.90   0.058       \-
                                HB              2             345/904            1.96   0.050       \-
                                Caucasian       4             904/2,413          2.86   **0.004**   3.81 (1.52--9.52)
                                Asian           2             57/139             1.89   0.059       \-
                                Severe sepsis   3             352/2,037          2.14   **0.032**   3.51 (1.11--11.05)
                                Septic shock    4             404/2,148          2.89   **0.004**   4.50 (1.62--12.51)
  **GA vs. GG**                 overall         9             1,916/3,372        0.53   0.595       \-
                                PB              5             1,214/1,182        2.77   **0.006**   1.46 (1.12--1.91)
                                HB              3             382/1,018          1.66   0.098       \-
                                Caucasian       4             904/2,413          0.80   0.423       \-
                                Asian           4             975/845            2.25   **0.024**   1.44 (1.05--1.98)
                                Severe sepsis   5             817/2,749          0.95   0.342       \-
                                Septic shock    4             404/2,148          0.02   0.985       \-
  **GA+AA vs. GG**              overall         9             1,916/3,372        1.17   0.243       \-
                                PB              5             1,214/1,182        3.01   **0.003**   1.51 (1.15--1.97)
                                HB              3             382/1,018          1.14   0.254       \-
                                Caucasian       4             904/2,413          0.18   0.858       \-
                                Asian           4             975/845            2.49   **0.013**   1.49 (1.09--2.05)
                                Severe sepsis   5             817/2,749          0.59   0.558       \-
                                Septic shock    4             404/2,148          0.64   0.519       \-
  **AA vs. GG+GA**              overall         6             961/2,552          3.41   **0.001**   4.24(1.85--9.72)
                                PB              3             296/476            1.83   0.068       \-
                                HB              2             345/904            1.99   **0.046**   3.35 (1.02--10.99)
                                Caucasian       4             904/2,413          2.88   **0.004**   3.87 (1.54--9.69)
                                Asian           2             57/139             1.82   0.069       \-
                                Severe sepsis   3             352/2,037          2.19   **0.029**   3.63 (1.14--11.50)
                                Septic shock    4             404/2,148          2.85   **0.004**   4.45 (1.59--12.41)
  **carrier A vs. carrier G**   overall         9             1,916/3,372        1.14   0.254       \-
                                PB              5             1,214/1,182        2.73   **0.006**   1.45 (1.11--1.89)
                                HB              3             382/1,018          0.95   0.342       \-
                                Caucasian       4             904/2,413          0.07   0.948       \-
                                Asian           4             975/845            2.27   **0.023**   1.44 (1.05--1.97)
                                Severe sepsis   5             817/2,749          0.45   0.653       \-
                                Septic shock    4             404/2,148          0.65   0.517       \-

PB: population-based control; HB: hospital-based control; OR: odd ratio; CI: confidence interval; -: ORs (95% CIs) not provided for *P*~association~ \>0.05.

![*TNF-α* rs361525 subgroup analysis based on ethnicity using the GA vs. GG genetic model](oncotarget-08-111456-g003){#F3}

Heterogeneity, publication bias, and sensitivity analysis {#s2_4}
---------------------------------------------------------

For *TNF-α* rs1800629, we applied the random-effect model in the allele, heterozygote, dominant, and carrier Mantel-Haenszel analyses, due to the following data (Table [4](#T4){ref-type="table"}): A vs. G (I^2^=55.7%, heterogeneity *P*\<0.001); GA vs. GG (I^2^=56.9%, *P*\<0.001); GA+AA vs. GG (I^2^=58.2%, *P*\<0.001); carrier A vs. carrier G (*P*\<0.05). For *TNF-α* rs361525, the fixed-effected model was used for all comparisons (Table [4](#T4){ref-type="table"}, all I^2^\<50.0%, heterogeneity *P*\>0.05). We performed Begg's test and Egger's test to evaluate publication bias. We did not observe any large publication bias (*P*\>0.05 in both Begg's test and Egger's test), except in the rs1800629 Egger's test in the AA vs. GG (*P*=0.042) and AA vs. GG+GA (*P*=0.041) models (Table [5](#T5){ref-type="table"}). Figure [4](#F4){ref-type="fig"} shows the Begg's funnel plot and Egger's publication bias plot for the GA vs. GG *TNF-α* rs1800629 meta-analysis. Similar pooled ORs in our sensitivity analysis suggested that our data were reliable (Figure [5](#F5){ref-type="fig"} for the GA vs. GG model of *TNF-α* rs1800629; other data not shown).

###### Heterogeneity evaluation

  SNP         Comparison                I^2^    *P*-value     Model
  ----------- ------------------------- ------- ------------- --------
  rs1800629   A vs. G                   55.7%   **\<0.001**   Random
              AA vs. GG                 0.0%    0.828         Fixed
              GA vs. GG                 56.9%   **\<0.001**   Random
              GA+AA vs. GG              58.2%   **\<0.001**   Random
              AA vs. GG+GA              0.0%    0.892         Fixed
              carrier A vs. carrier G   37.1%   **0.029**     Random
  rs361525    A vs. G                   43.6%   0.077         Fixed
              AA vs. GG                 0.0%    0.961         Fixed
              GA vs. GG                 40.8%   0.095         Fixed
              GA+AA vs. GG              42.3%   0.085         Fixed
              AA vs. GG+GA              0.0%    0.974         Fixed
              carrier A vs. carrier G   27.8%   0.197         Fixed

SNP: single nucleotide polymorphisms.

###### Publication bias evaluation

  SNP         Comparison                Begg's test   Egger's test          
  ----------- ------------------------- ------------- -------------- ------ -----------
  rs1800629   A vs. G                   1.17          0.243          1.68   0.106
              AA vs. GG                 1.46          0.144          2.19   **0.042**
              GA vs. GG                 0.54          0.588          0.80   0.431
              GA+AA vs. GG              0.92          0.359          1.20   0.243
              AA vs. GG+GA              1.72          0.086          2.20   **0.041**
              carrier A vs. carrier G   1.13          0.260          1.49   0.148
  rs361525    A vs. G                   0.31          0.754          1.00   0.352
              AA vs. GG                 0.00          1.000          1.83   0.141
              GA vs. GG                 0.31          0.754          0.44   0.673
              GA+AA vs. GG              -0.10         1.000          0.76   0.469
              AA vs. GG+GA              0.00          1.000          1.59   0.186
              carrier A vs. carrier G   -0.10         1.000          0.72   0.496

SNP: single nucleotide polymorphisms.

![*TNF-α* rs1800629 publication bias analysis using the GA vs. GG genetic model\
Begg's funnel plot **(A)** Egger's publication bias plot **(B)**.](oncotarget-08-111456-g004){#F4}

![*TNF-α* rs1800629 sensitivity analysis using the GA vs. GG genetic model](oncotarget-08-111456-g005){#F5}

DISCUSSION {#s3}
==========

This updated literature search and meta-analysis comprehensively reassessed the association between *TNF-α* polymorphisms and sepsis risk in Asian/Caucasian populations. There are several advantages in terms of database searching, screening strategy study inclusion, and sample size. To date, three related meta-analyses have been published \[[@R36]-[@R38]\]. Teuffel, *et al.* performed the first of these in 2010, and reported that the GA or AA *TNF-α* rs1800629 genotypes were associated with increased sepsis risk \[[@R37]\]. Twenty-five articles \[[@R14], [@R16], [@R18], [@R25]-[@R28], [@R31], [@R39]-[@R55]\] were included in this meta-analysis, however several articles \[[@R39]-[@R49], [@R51]-[@R55]\] did not contain sufficient genotype frequency data in the case and/or control groups, or were not in line with Hardy-Weinberg Equilibrium (HWE). Additionally, no or mild sepsis was set as the control group in one included article \[[@R40]\], which may not have been appropriate for our meta-analysis. Another meta-analysis by Srinivasan, *et al.* only investigated the association between *TNF-α* rs1800629 and neonatal sepsis risk \[[@R36]\]. After rigorous screening, we enrolled 23 articles with 3,404 cases and 5,973 controls \[[@R13]-[@R35]\] in our *TNF-α* rs1800629 meta-analysis.

Our study included articles from a variety of databases and we performed statistical analyses using six genetic models. Previous meta-analyses were not performed using different genetic models, and the roles of the GA and AA genotypes were thus not evaluated \[[@R37]\]. Another recent meta-analysis by Zhang, *et al.* assessed 26 articles \[[@R13]-[@R16], [@R18], [@R23]-[@R26], [@R28]-[@R32], [@R34], [@R41], [@R44], [@R47]-[@R49], [@R51], [@R53], [@R56]-[@R59]\] and associated both the *TNF-α* rs1800629 and rs361525 polymorphisms with increased sepsis risk \[[@R38]\]. Here, we included only moderate and high quality articles (NOS score \>5) from 834 relevant articles from 2007 that contained complete case/control genotype data (GG, GA, AA). Genotype frequency distributions in controls must have been in line with HWE to be included in our analysis. We excluded three articles \[[@R41], [@R44], [@R57]\] inconsistent with HWE, and six \[[@R47]-[@R49], [@R51], [@R53], [@R59]\] that did not provide sufficient case/control genotype data. We excluded another article \[[@R56]\] that may have been the source of the high heterogeneity in the *TNF-α* rs1800629 Asian patient subgroup analysis. Additionally, our study included eight new articles \[[@R17], [@R19]-[@R22], [@R27], [@R33], [@R35]\] that were not assessed by Zhang, *et al.* \[[@R38]\].

Our stratified analysis of severe sepsis and septic shock included only articles that specified sepsis type. Our subgroup meta-analyses based on controls (HB/PB), showed that the *TNF-α* rs1800629 G/A genotype was linked to increased sepsis risk in both groups. However, *TNF-α* rs361525 and sepsis risk were positively correlated in the PB, but not HB group. Thus, the presence of other diseases may influence the genetic role of *TNF-α* rs361525, but not *TNF-* rs1800629 in sepsis risk.

Our study was subject to certain limitations. First, more studies with larger sample sizes and high qualities are needed for enhanced statistical power. We only observed the potential association between *TNF-α* rs1800629 and severe sepsis risk for the allele, dominant, and carrier models. *TNF-α* rs361525 was also found be slightly linked to the risk of severe sepsis or septic shock for the homozygote and recessive models. Thus, our lack of strong evidence for associations between the two SNPs and sepsis risk merits more case-control studies. Second, we found high heterogeneity between studies in some genetic comparisons. This may be caused at least in part by the complexity of the sepsis etiology and the non-uniformity of diagnostic criteria. Finally, more data are needed to clarify the genetic roles and prognostic significance of distinct cytokine gene combinations in sepsis risk. Different SNP linkages of the *TNF-α* gene should be considered as well.

In conclusion, our findings suggest a positive association between the G/A genotype of the *TNF-α* rs1800629 and rs361525 polymorphisms and sepsis risk in the Asian population, which is partly in line with the findings of Teuffel, *et al.* \[[@R37]\] and Zhang, *et al.* \[[@R38]\]. Abnormal TNF-α is implicated in the pathogenesis of sepsis. For example, *TNF-α* expression was closely related to neonatal sepsis in very low birth weight infants in Spain \[[@R60]\]. It may be that mutation in the *TNF-α* promoter region from common G (guanidine) to rare A (adenosine) at position -308 (rs1800629) or -238 (rs361525) affects normal TNF-α production, secretion, or function in sepsis patients \[[@R8]\].

MATERIALS AND METHODS {#s4}
=====================

Records identification {#s4_1}
----------------------

We identified potential records from six databases (PubMed, WOS, EMBASE, CNKI, WANFANG, and Scopus). We performed a PRISMA (preferred reporting items for systematic reviews and meta-analyses \[[@R61]\])-compliant database search and study selection, and the relevant meta-analysis papers were referred \[[@R62]-[@R64]\]. Two authors (Yixin Zhang, Xiaoteng Cui) independently removed duplicate studies and assessed record eligibilities according to our exclusion/inclusion criteria. Exclusion criteria included: a) meta-analysis; b) review, editorials, and perspectives; c) congress abstract or poster; d) other gene or other disease; e) not a *TNF-α* SNP or no clinical data; f) lack of control data; g) did not contain genotype data or the genotype distributions were not in line with HWE.

According to Newcastle-Ottawa Scale (NOS) requirements (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>), we evaluated methodological quality independently. Included studies had a NOS score \>5, and provide the following data: first author name, publication year, patient ethnicity, SNP, sample size, and genotype frequency within case-control studies and genotyping assays.

Quantitative synthesis and heterogeneity {#s4_2}
----------------------------------------

We used the Mantel-Haenszel test to determine *P*-values, pooled ORs, and 95% CIs for the following six genetic models: A vs. G (allele); AA vs. GG (homozygote); GA vs. GG (heterozygote); GA+AA vs. GG (dominant); AA vs. GG+GA (recessive); and carrier A vs. carrier G (carrier). *P*\<0.05 represented a statistically significant difference between case and control studies. We also assessed the heterogeneity between studies using the Q statistic and I^2^ test. High heterogeneity was likely when Q statistic *P*\<0.05 or I^2^\>50%. In this situation, we employed the random-effect model, not the fixed-effect model. We also performed a series of subgroup meta-analyses according to three factors: source of control \[PB (population-based) or HB (hospital-based)\], ethnicity (Caucasian or Asian), and sepsis severity (sepsis, severe sepsis, or septic shock).

Publication bias and sensitivity analysis {#s4_3}
-----------------------------------------

We evaluated publication bias using both Begg's test and Egger's test. *P*\>0.05 in both tests would exclude a large publication bias. We also performed a sensitivity analysis to evaluate the robustness of our data. All analyses were performed using Stata/SE 12.0 software (StataCorp, USA).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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